Navigation Links
Pathfinder Initiates Minimally Invasive Surgical Navigation Study
Date:11/15/2010

NASHVILLE, Tenn., Nov. 15, 2010 /PRNewswire/ -- Pathfinder Therapeutics, Inc. has initiated a clinical study to assess the value of Explorer™, its image-guided surgical platform, in minimally invasive liver resections and ablations.  Clinical sites participating in the study include: Memorial Sloan-Kettering Cancer Center, University of Pittsburgh Medical Center, Providence Portland Medical Center, and UNC-Chapel Hill.

Minimally invasive procedures are performed through a few small incisions rather than one large incision.  As a result, these techniques can significantly reduce postoperative pain and patient recovery time compared with traditional surgery.

"We are excited to partner with these highly-regarded institutions to build upon the success of previous clinical studies showing that Explorer™ can provide accurate instrument tracking and guidance during open liver procedures. Despite its known benefits, minimally invasive liver surgery has not attained widespread use, in part due to the advanced skills and technological experience required to perform such procedures safely.  Explorer™ combines state-of-the-art surgical navigation and 3D visualization of preoperative imaging, thereby facilitating the transition from standard techniques to novel laparoscopic techniques for surgeons with less experience and formal training while also providing assistance to highly experienced surgeons," said Skip Goode, CEO of Pathfinder.

As part of the study, preoperative CT or MR imaging is registered to the intraoperative position of the liver, providing surgeons with enhanced visualization of the liver anatomy as well as real-time positioning of surgical instruments, including resection and ablation devices.  Rather than guess where underlying vessels and tumors are, surgeons can be confident they are precisely targeting the anatomical structures they have planned on, thus minimizing costly mistakes which can increase the risk of postoperative complications.  This ability to "see through the liver" in 3D is especially helpful during minimally invasive procedures, where the surgeon is unable to physically manipulate the liver as is possible during traditional surgery.

About Pathfinder Therapeutics, Inc.

Pathfinder Therapeutics, Inc. is a medical device company dedicated to increasing the number and effectiveness of surgeries on abdominal and other soft tissue organs.  Pathfinder is the first company to receive FDA clearance for a medical device to navigate liver surgery using preoperative medical images. The Explorer™ navigation system uses state-of-the-art optical tracking and surface registration techniques to show surgeons where they are in the context of their target organ and underlying structures.  For more information, go to www.pathsurg.com.


'/>"/>
SOURCE Pathfinder Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD
2. American Regent Initiates Voluntary Recall of Magnesium Sulfate Injection, USP 50% (25 grams/50 mL), 50mL Single Dose Vial Lot # 0491
3. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
4. Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor
5. Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinsons Disease
6. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
7. Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)
8. Echo Therapeutics Initiates Needle-Free Biosensor Program for Continuous Lactate Monitoring
9. LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine
10. ISTA Pharmaceuticals Initiates Phase 3 Clinical Program for REMURA™ in Dry Eye Disease
11. N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... -- Novavax, Inc., (Nasdaq: NVAX ) today announced that ... its RSV F protein recombinant nanoparticle vaccine candidate (RSV F ... in the journal Vaccine (the data ... conferences). The Company previously announced top line results ... RSV F Vaccine with the goal of protecting infants from ...
(Date:6/5/2017)... CINCINNATI , June 5, 2017 The ... a brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has been ... Cincinnati Enquirer . Results are based on ... specializing in organizational health and workplace improvement. The survey measures ... ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly and ... that results from the Phase 3 MONARCH 2 ... & 6 inhibitor, in combination with fulvestrant, significantly ... fulvestrant alone in women with hormone-receptor-positive (HR+), human ... cancer who have relapsed or progressed after endocrine ...
Breaking Medicine Technology:
(Date:6/26/2017)... , ... June 26, 2017 , ... ... in the country, today announced the hiring of Richard Robinson as chief operating ... leadership and operations experience, with a proven track record of simplifying business processes ...
(Date:6/26/2017)... , ... June 26, 2017 , ... ... staff, and consumers are seeing lots of red these days. According to recent ... charges that result from medical coding errors(1). Some studies point to Electronic Health ...
(Date:6/25/2017)... ... ... Create a feel-good lyric music video in Final Cut Pro X with ProLyric from Pixel ... in the lyrics to any song. ProLyric flies in the text for each section and ... be added modularly for optimal control. ProLyric makes editing any music video or text-based production ...
(Date:6/25/2017)... ... 25, 2017 , ... With a heatwave currently bearing down on Northern California pushing temperatures to ... Being swimsuit ready is easy with laser hair removal. , The process of summer ... burdensome routine when all you want to do is get out, dive in and cool ...
(Date:6/24/2017)... Ronkonkoma, New York (PRWEB) , ... June 24, ... ... now joined the Dental365 family. Located at 217 Portion Road in Lake Ronkonkoma, ... also open evenings and weekends so that visits to the dentist fit into ...
Breaking Medicine News(10 mins):